The company intends to use the funds for the continued advancement of its lead clinical programs in chronic urticaria and atopic dermatitis, including multiple Phase 2 studies of EVO756, a potent, highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2).

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Undisclosed
Palo Alto, CA Undisclosed
USA

Phone

Undisclosed

Website

www.evommune.com

Email Address

Undisclosed

Overview

Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future. Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life. Many immunology-focused medications give patients a temporary fix to a longer-term problem--addressing symptom control rather than the root cause of disease.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Luis Peña

Chief Financial Officer

Kyle Carver

Chief Medical Officer

Eugene Bauer

Chief Scientific Officer

Jeegar Patel

Browse more venture capital transactions:

Prev: 10/31/2024: JUUNOO venture capital transaction
Next: 10/31/2024: Lingo venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary